Esra is an Associate Research Consultant in the Modeling and Meta-Analysis department in Rotterdam, the Netherlands. She is responsible for cost-effectiveness and budget impact model development and adaptation, meta-analyses, survival analyses, pharmacoeconomic dossiers and literature reviews.
Before joining Pharmerit, Esra worked as a researcher at the Erasmus School of Health Policy and Management. As a researcher, she studied the complexity of care between academic, top-clinical and general hospitals. Furthermore, she conducted a cost-effectiveness analysis on Parent Child Intervention Therapy (PCIT-HOME), which is an evidence-based treatment for young children with behavioral problems.
Esra holds a bachelor degree in Health Policy and Management and a master degree in Health Economics, both obtained from Erasmus University. During her bachelor, she won a thesis award for her research on the application of multi criteria decision analysis (MCDA) in the Dutch drug reimbursement system. In this study, she used the MCDA framework to systematically compare the oncology drug nivolumab with other reimbursement eligible drugs based on their performance on multiple reimbursement criteria. For her master thesis, she developed a cost-effectiveness model for atezolizumab in third line non-small cell lung cancer patients in the Netherlands.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.